In September 2025, the FDA sent thousands of warning letters and issued approximately 100 cease-and-desist letters to companies regarding their use of misleading direct-to-consumer pharmaceutical advertisements. The agency also published a green list of acceptable GLP-1 compounding ingredients intended to regulate ingredient sourcing and reduce the risk of unsafe compounded products
Aim for consistent hydration throughout the day
Diary cards were provided to participants on days 1, 7, 14, and 21, onto which participants were instructed to record their temperature, adverse events (AEs), medication, and supplementation
Patients with a history of pancreatitis require particular caution, as GLP-1 receptor agonists have been associated with rare cases of acute pancreatitis in clinical trials and post-marketing surveillance
52 Rare cases of suicidality have been reported, although preliminary evaluation using the FDA Adverse Reporting System, post hoc analysis of the STEP clinical trials, and 1 large cohort study have not confirmed any definitive link